Myeloid cells are the most abundant haematopoietic cells in the human body and have diverse functions. All myeloid cells arise from multipotent haematopoietic stem cells (HSCs) that develop into mature myeloid cells through sequential steps of differentiation. However, myeloid progenitors do not form a hierarchical system but can instead be considered as a network of cells that can differentiate into various subsets of more-specialized myeloid cells (FIG. 1) .
The three groups of terminally differentiated myeloid cells -macrophages, dendritic cells (DCs) and granulocytes -are essential for the normal functions of the innate and adaptive immune systems. Classically, these cells protect organisms from pathogens, eliminate dying cells and mediate tissue remodelling. Although the contribution of myeloid cells to tumour pathogenesis has been recognized for over 100 years, only during the past two decades has their crucial role in promoting tumour angiogenesis, cell invasion and metastasis been appreciated (reviewed in . Mast cells have also been implicated in the regulation of tumour progression (reviewed in REF. 4 ). Mounting evidence indicates that the tumour microenvironment alters myeloid cells by converting them into potent immunosuppressive cells. In recent years the concept of myeloid-derived suppressor cells (MDSCs) (described below) has emerged. However, the wealth of new information concerning myeloid cells in cancer has also produced confusion. In most studies, individual myeloid cell populations have been examined independently, generating fragmented information that has contributed to a disjointed view of the role of myeloid cells in immune responses in cancer. In addition, their overlapping expression of cell-surface markers has made it difficult to distinguish between different myeloid cell populations, further obscuring the nature of specific myeloid cell subsets in cancer. These complications limit our understanding of myeloid cell biology and hamper attempts to develop and optimize therapeutic interventions.
In this Review, we present a cohesive view of the effects of tumours on myeloid cells. Our goal is not to provide a comprehensive overview of the changes in individual populations of myeloid cells, as this has been accomplished in other recent reviews. Instead, we briefly summarize the effects that tumours have on terminally differentiated myeloid cell subsets and then focus on discussing myeloid cell interactions and responses during tumour development as an intricately connected, single (albeit complex) system.
Dendritic cells
DCs are terminally differentiated myeloid cells that specialize in antigen processing and presentation. DCs differentiate in the bone marrow from various progenitors [5] [6] [7] [8] . They can also differentiate from monocytes under certain conditions, although most DCs in mouse lymphoid organs are not derived from monocytes 5, 9 . By contrast, monocytes are the major precursors of DCs in humans 10 . Two major subsets of DCs are currently recognized: conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Although these cells share some common progenitors, their differentiation is controlled by distinct genetic programmes and they have different morphologies, markers and functions 11 ( Abstract | Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and are a collection of distinct cell populations with many diverse functions. The three groups of terminally differentiated myeloid cells -macrophages, dendritic cells and granulocytes -are essential for the normal function of both the innate and adaptive immune systems. Mounting evidence indicates that the tumour microenvironment alters myeloid cells and can convert them into potent immunosuppressive cells. Here, we consider myeloid cells as an intricately connected, complex, single system and we focus on how tumours manipulate the myeloid system to evade the host immune response. Pathogen-associated molecular patterns (PAMPs) . These are molecular motifs that are found in pathogens but not in mammalian cells. Examples include terminally mannosylated and polymannosylated compounds, which bind to the mannose receptor CD206, and various microbial products that activate host Toll-like receptors, such as bacterial lipopolysaccharides, hypomethylated DNA, flagellin and double-stranded RNA.
activation and maturation in response to 'dangerous' stimuli. Differentiated DCs reside in tissues as 'immature' cells that actively take up tissue antigens but are poor antigen presenters and do not promote effector T cell differentiation. Only functionally activated DCs can effectively stimulate immune responses. DCs are activated in response to stimuli associated with bacteria, viruses or damaged tissues; such stimuli are commonly referred to as pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The activation of DCs leads to profound changes in their gene expression, resulting in increased expression of co-stimulatory molecules and cytokines that promote T cell activation and also in the upregulation of chemokine receptors that drive the migration of DCs to lymphoid tissues. pDCs constitute a minor population of DCs; they have a morphology reminiscent of plasma cells, express Toll-like receptor 7 (TLR7) and TLR9 (this receptor is not expressed by human cDCs) and produce large amounts of interferon-α (IFNα) in response to the activation of their TLRs by viral nucleic acids or self DNA 11 . A more detailed discussion of DC biology can be found in recent reviews 9, 12 .
Effects of cancer on DCs. That cancer can have profound effects on the function of DCs has been known for more than 20 years. It is well established that DCs in tumourbearing hosts do not adequately stimulate an immune response, and this potentially contributes to tumour evasion of immune recognition. Evidence from numerous studies strongly indicates that abnormal myelopoiesis is the dominant mechanism responsible for DC defects in cancer 13 . This abnormal differentiation produces at least three main results: decreased production of mature functionally competent DCs; increased accumulation of immature DCs at the tumour site; and increased production of immature myeloid cells 13 . In recent years, multiple clinical studies have confirmed the findings of earlier studies and have indicated that there is a decreased presence and defective functionality of mature DCs in patients with breast 14 , non-small cell lung 15 , pancreatic 16 , cervical 17 , hepatocellular 18 or prostate cancer, or glioma 19 . In addition to the many tumour-derived soluble factors previously implicated in abnormal DC differentiation, such as vascular endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF) and interleukin-6 (IL-6), recent studies have shown that other factors present in the tumour microenvironment impair normal DC functions. The tumour microenvironment is predominantly characterized by hypoxia, accumulation of extracellular adenosine, increased levels of lactate and a decreased pH. DC migration and function are severely impaired by hypoxia and adenosine 20, 21 . The transcription factor hypoxia-inducible factor 1α (HIF1α) is upregulated by DCs in the hypoxic tumour environment and was shown to induce the expression of adenosine receptor A2B by human DCs, causing these DCs to drive the development of T H 2 cells (T helper 2 cells) rather than that of T H 1 cells, which have more-potent antitumour activity 22 . DCs differentiated in the presence of adenosine had impaired allostimulatory activity in a mixed leukocyte reaction, and they expressed higher levels of the pro-angiogenic cytokine VEGF, the pro-inflammatory cytokines IL-6 and IL-8, and the immunosuppressive mediators IL-10, cyclooxygenase 2 (COX2), transforming growth factor-β (TGFβ) and indoleamine 2,3-dioxygenase (IDO) 23 . Addition of lactic acid during DC differentiation in vitro also induced a phenotype comparable with that of tumour-associated DCs. Blockade of lactic acid production reverted the tumour-induced DC phenotype to normal 24 . DCs found in the peripheral blood and lymphoid organs of tumour-bearing mice or of patients with cancer, and especially DCs closely associated with the tumour, have an increased accumulation of lipids. This is mediated primarily through upregulation of macrophage scavenger receptor types I and II, and it impairs the ability of DCs to process soluble proteins and stimulate tumour-specific T cell responses 25 . Some DCs in tumour-bearing hosts actively suppress T cell function, and both phenotypically immature and phenotypically mature DCs may be conditioned by the environment to support immune tolerance or immunosuppression 26 The accumulation of IDO-expressing DCs (most of which are pDCs) in tumour-bearing mice and in some patients with cancer 32, 33 provides another possible mechanism of immune suppression, as IDO activity limits T cell growth by depleting l-tryptophan and also promotes T cell apoptosis by generating l-tryptophan metabolites and by altering redox potentials through consumption of superoxide radicals. Evidence supports the hypothesis that IDO-expressing DCs enhance the suppressive abilities of forkhead box P3 (FOXP3)-expressing regulatory T cells (T Reg cells) in certain settings of chronic inflammation 34 . As mentioned above, such immunosuppressive activities are primarily associated with DCs localized in tumour sites. However, abnormal DC differentiation and defective DC function is a systemic phenomenon that affects the myeloid cell lineage during cancer, as described in more detail below.
Macrophages
Macrophages are a group of terminally differentiated myeloid cells that are closely related to DCs. They are tissue-resident cells derived from monocytes circulating in peripheral blood. The macrophage population See the main text for references and for a more detailed discussion of the molecules and cellular interactions that have been described for mouse macrophages and for human macrophages in the tumour environment. COX2, cyclooxygenase 2; EGF, epidermal growth factor; IFNβ, interferon-β; IL-4Rα, IL-4 receptor α-chain; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; PDL1, PD1 ligand 1; TGFβ, transforming growth factor-β.
Regulatory T cells (T Reg cells).
A specialized subset of CD4 + T cells that can suppress both innate and adaptive immune responses. These cells provide a crucial mechanism for the maintenance of peripheral self-tolerance, but may also limit the effectiveness of antitumour immune responses.
includes a broad range of cells, the markers and functions of which reflect their tissue microenvironment (TABLE 1) . Their function in healthy individuals is to eliminate infectious agents, promote wound healing and regulate adaptive immunity (reviewed in REF. 35 ).
The terminology 'M1 macrophage' and 'M2 macrophage' was coined to describe the different functional states of macrophages and was originally based on studies of mouse macrophages 36 . M1 or 'classically activated' macrophages are activated by IFNγ and bacterial products, express high levels of IL-12 and low levels of IL-10, and are tumoricidal. By contrast, M2 or 'alternatively activated' macrophages are activated by IL-4, IL-10, IL-13 and glucocorticoid hormones, express high levels of IL-10 and low levels of IL-12, and facilitate tumour progression. As discussed by Mantovani 37 , the M1/M2 nomenclature is useful but is oversimplified because macrophages form a continuum of phenotypes. Although there are some differences between M2-like mouse and human macrophages, phenotypically and functionally the macrophages in these two species are quite similar (TABLE 1) .
The role of macrophages in promoting tumorigenesis.
There is extensive literature demonstrating that, in both mice and humans, macrophages are co-opted during malignancy to facilitate tumour growth (reviewed in REFS 1, 2, 37, 38) (FIG. 2) . Their presence is associated with poor clinical outcome 1, 38 , and their pivotal role in cancer was recently highlighted by the demonstration that TAMs with a specific gene signature are associated with primary treatment failure in patients with Hodgkin's lymphoma 39 . TAMs are M2-like macrophages, and they mediate their effects via both non-immune and
Plasminogen
Plasminogen is the inactive precursor of plasmin, a serine protease involved in the dissolution of fibrin blood clots. A causal role has been suggested for plasmin generation in cancer cell invasion through extracellular matrix remodelling.
Invariant NKT cells (Invariant natural killer T cells).
A type of lymphocyte thought to be particularly important in bridging innate and adaptive immunity. These cells express a particular T cell receptor variable gene segment (Vα14 in mice and Vα24 in humans) that is precisely linked to a particular joining (Jα) gene segment. Typically, NKT cells co-express cell-surface markers encoded by the natural killer locus, and are activated by recognition of CD1d.
immune mechanisms. Their non-immune mechanisms include the promotion of angiogenesis 40 , the facilitation of tumour cell invasion and metastasis 41 , and the protection of tumour cells from chemotherapy-induced apoptosis 42 (see also reviews in REFS 1,2,37,38,43). TAMs sabotage antitumour immunity by eliminating M1 macrophage-mediated innate immune responses and by impairing T cell activation. Studies using transgenic mice have showed that IL-12 produced by M1 macrophages promotes the activation of natural killer (NK) cells and T H 1 cells, which facilitate the activation of cytotoxic T lymphocytes (CTLs). However, because TAMs do not produce IL-12, they do not contribute to the activation of NK cells and T H 1 cells. Instead, they produce IL-10 and drive the development of T H 2 cells. T H 2 cells do not support the development of CTL responses, and their production of IL-4 drives the development of TAMs 44 . In addition, IL-10 that is produced by macrophages in the inflamed intestinal lamina propria is required to maintain T Reg cell activity and prevent autoimmune colitis 45 , raising the possibility that TAM-derived IL-10 may also promote tumour progression by enhancing T Reg cell activity.
TAMs are ineffective antigen-presenting cells, and they produce CC-chemokine ligand 22 (CCL22), which attracts T Reg cells that inhibit T cell activation 46 . Secretion of prostaglandin E2 (PGE2) and TGFβ 47 by TAMs further contributes to immune suppression. TAMs can also cause T cell apoptosis through their expression of PD1 ligand 1 (PDL1), which binds to its receptor programmed cell death protein 1 (PD1) on activated T cells 48 , and mouse macrophages produce ARG1, which deprives T cells of the l-arginine that is necessary for their growth 49 . A similar mechanism is also used by MDSCs (see below). Inflammation is important for the recruitment of macrophages to tumour sites, and the pro-inflammatory mediators CCL2 (REF. 50 ) and plasminogen 51,52 have essential roles in this process.
TAM polarization. Because different areas of solid tumours have distinct microenvironments, the TAMs found within an individual tumour vary in phenotype and function. Seven subsets of TAMs have been identified in mouse mammary carcinoma and lung adenocarcinoma based on their expression of LY6C, MHC class II molecules, CX 3 C-chemokine receptor 1 (CX 3 CR1), CC-chemokine receptor 2 (CCR2) and CD62L (also known as L-selectin). These subsets have different half-lives, and their relative frequencies change as the tumour microenvironment evolves with disease progression 53 . Pro-angiogenic TAMs may express the angiopoietin receptor TIE2 (REF. 54) and/or have low expression levels of MHC class II mol ecules, and they localize to hypoxic regions 53 . TAMs that promote early tumour cell invasion are enriched for WNT7B, a protein that is involved in normal developmental and repair responses 55 . Tumour-derived TGFβ and PGE2 promote the differentiation of macrophages that express high levels of GR1 and low levels of markers associated with M1-type macrophages 47 .
T cells have an important role in macrophage regulation during tumorigenesis. In a mouse model of breast cancer driven by transgenic expression of the polyomavirus middle T antigen, mice with mammary adenocarcinomas developed T H 2 cells that produced IL-4, which polarized TAMs to an M2 phenotype. These TAMs produced epidermal growth factor (EGF), which initiates tumour cell invasion, migration and metastasis by signalling through the corresponding receptor on malignant mammary epithelial cells 44 . 58 . A recent study in a mouse B16 melanoma model has shown that B cells decrease the production of tumour necrosis factor (TNF), IL-1β and CCL3 by macrophages, whereas they increase macrophage production of IL-10. This facilitates protumour macrophage activity as well as the synthesis of the M2-associated markers YM1 (also known as CHI3L3) and FIZZ1 (also known as RELMα) 59 . In another report, autoantibodies polarized leukocytes, including macrophages, towards a tumour-promoting phenotype by interacting with activating Fc receptors on the leukocytes 60 . Polarization of macrophages towards an M2 phenotype is also mediated directly by tumour cells. For example, human ovarian cancer cells cause macrophages to produce increased levels of IL-10, IL-1β, CCL5, CCL22, matrix metalloproteinase 7 (MMP7), MMP9, CD206 and CD163. Tumour cell-derived TNF was partially responsible for this polarization through its induction of macrophage scavenger receptor types I and II 62 .
Granulocytes
Granulocytes are myeloid cells that are characterized by the presence of cytoplasmic granules and a specific nuclear morphology. The most abundant type of granulocytes in the body is neutrophils, which are also commonly referred to as polymorphonuclear leukocytes owing to their polylobed nuclei. Neutrophils possess a complex machinery to engulf and destroy bacteria. Neutrophils are not released from the bone marrow until they reach full maturity, but during inflammation neutrophil precursors (myelocytes and promyelocytes) can be released 62 . Human tumours can be infiltrated by mature granulocytes, the numbers of which can be independent prognostic factors for tumour recurrence [63] [64] [65] [66] . Recent evidence has linked granulocytes, and particularly neutrophils, with tumour angiogenesis and metastasis, and Nature Reviews | Immunology has provided initial clues about the immunoregulatory roles of these cells in cancer. Tumour cells and tumourassociated stromal cells produce neutrophil-attracting CXC-chemokines and prokineticin 2 (the mammalian orthologue of BV8) 67, 68 . In the lungs, tumour-derived granulocyte colony-stimulating factor (G-CSF) also mobilizes granulocytes to pre-metastatic niches and supports subsequent metastasis formation, whereas prokineticin 2 aids tumour cell migration through the activation of prokineticin receptor 1 (REF. 69 ). It is likely that granulocytes facilitate the angiogenic switch by expressing MMP9, which promotes tumour angiogenesis by inducing VEGF expression in neoplastic tissue 70 . Mobilized granulocytes also release elastase, which then enters endosomal compartments of neoplastic cells and degrades insulin receptor substrate 1 (IRS1). Degradation of IRS1 facilitates interactions between phosphoinositide 3-kinase (PI3K) and the receptor for the mitogen platelet-derived growth factor (PDGF), thus promoting tumour cell proliferation 71 . In contrast to these observations, a recent study demonstrated that, in mice bearing 4T1 breast tumours, neutrophils inhibited the formation of tumour metastases through direct antitumour effects mediated by reactive oxygen species (ROS) 72 . These new data revisit the old concept of tumour-cytotoxic neutrophils and suggest a possible dichotomic polarization of neutrophils. Similarly to macrophages, neutrophils have been shown to shift from an antitumoural 'N1' phenotype to a pro-tumoural 'N2' phenotype in the cancer environment 73 . TGFβ drives the N2 phe notype, and TGFβ blockade promotes an N1 phenotype with antitumour activity. In lung adenocarcinoma and mesothelioma models, TGFβ induces tumour-infiltrating neutrophils to develop a pro-tumoural phenotype, which is characterized by ARG1 expression and low levels of TNF, CCL3 and intercellular adhesion molecule 1 (ICAM1). In tumour-bearing animals, depletion of N2 neutrophils led to an increase in CD8 + T cell activity 73 . In line with these findings, serum amyloid A1 protein induced the expansion of IL-10-secreting neutrophil populations that were able to suppress the antigen-specific proliferation of CD8 + T cells in human melanomas 74 . However, IL-10 production by activated human neutrophils was not confirmed in a subsequent study 75 .
Myeloid cells as a single integrated system
Neoplastic cells condition distant sites, such as the bone marrow and spleen, by releasing soluble factors that drive the accumulation of myeloid cells; these myeloid cells subsequently promote neovascularization and metastasis. This creates a tumour-driven 'macro environment' . As discussed above, this macroenvironment conditions DCs, macrophages and granulo cytes to become immunosuppressive. However, the most prominent effect is the accumulation of highly immunosuppressive, immature myeloid cells. These cells were named MDSCs to highlight their common myeloid origin and immunoregulatory properties 76 (TABLE 1) . Immature myeloid cells with the same pheno type as MDSCs are continually generated in the bone marrow of healthy individuals and differentiate into mature myeloid cells without causing detectable immunosuppression. However, in cancer, myeloid cell differentiation is diverted from its normal pathwaywhich leads to the terminal differentiation of mature macrophages, DCs and granulocytes -towards a pathway that favours the differentiation of pathological MDSCs (FIG. 3) .
Characteristics of MDSCs. MDSCs were originally identified in tumour-bearing mice as cells that co-express CD11b and GR1; however, their phenotype in cancer is rather diverse 77, 78 . Currently, two main MDSC populations have been characterized: monocytic MDSCs and polymorphonuclear MDSCs (also known as granulocytic MDSCs) (TABLE 1) .
In tumour-bearing mice, the polymorphonuclear MDSC subset is the prevalent population of MDSCs. Polymorphonuclear MDSCs suppress antigenspecific CD8 + T cells predominantly by producing ROS. Polymorphonuclear MDSCs represent the major subset of circulating MDSCs; however, they are less immunosuppressive than monocytic MDSCs when assessed on a per cell basis [79] [80] [81] . In human studies, the number of monocytic MDSCs, but not of polymorphonuclear MDSCs, correlated directly with suppression of in vitro T cell activation 82 . In addition to their specific markers (TABLE 1) , monocytic MDSCs express varying levels of classic monocyte markers, such as F4/80 (also known as EMR1), CD115 (also known as M-CSFR), 7/4 (also known as LY6B) and CCR2 83) . They suppress CD8 + T cells predominantly via expression of the enzymes ARG1 and inducible nitric oxide synthase (iNOS) and through the production of reactive nitrogen species [79] [80] [81] . 97 . Second, polymorphonuclear MDSCs express higher levels of CD115 and CD244 than neutrophils but lower levels of CXC-chemokine receptor 1 (CXCR1) and CXCR2 (REFS 97, 98) . Finally, compared with neutrophils, polymorphonuclear MDSCs are less phagocytic, express higher levels of ARG1 and myeloperoxidase, have increased ROS production and show reduced chemotaxis towards supernatants from human carcinomas 97, 98 .
Similarly, although monocytic MDSCs and inflammatory monocytes share a common phenotype and morphology, these cell populations are functionally distinct. Monocytic MDSCs are highly immunosuppressive, as they express, among other factors, high levels of both iNOS and ARG1. By contrast, iNOS and ARG1 are not coordinately upregulated in monocytes. Furthermore, although in M1 macrophages iNOS expression is a hallmark of a tumoricidal phenotype, in monocytic MDSCs iNOS expression promotes suppressive activities 36 . This shift in iNOS activity probably reflects the interplay of iNOS with other enzymes expressed by MDSCs, such as ARG1 and NADPH oxidase, as the coordinated activity of these enzymes was shown to promote the production of peroxynitrite, which inhibits the proliferation, effector functions and migration of T cells [99] [100] [101] [102] . Although differences exist in the expression of ARG1 and iNOS among mouse and human myeloid cells (for example, ARG1 is constitutively expressed by human granulocytes 103 but not monocytes), evidence indicates that human MDSCs can also co-express these enzymes 96, 104 . The MDSC population includes direct progenitors of DCs, macrophages and granulocytes. After 24 hours of in vitro culture, polymorphonuclear MDSCs phenotypically and functionally resemble neutrophils 97 . Culture of tumour-derived MDSCs in the absence of tumour-derived factors, or the transfer of MDSCs to tumour-free recipients, results in the generation of mature macrophages and DCs [105] [106] [107] . By contrast, the presence of tumour-derived soluble factors or adoptive transfer into tumour-bearing hosts promotes the differentiation of MDSCs into immunosuppressive macrophages 107, 108 . MDSCs can also differentiate into DCs following transfer into tumour-bearing recipients 109 , but whether these DCs are immunosuppressive is not currently known. Furthermore, hypoxia in the tumour microenvironment drives the differentiation of MDSCs into TAMs 109, 110 (FIG. 3) .
Immunomodulatory functions of MDSCs.
MDSCs exploit a plethora of redundant mechanisms to influence both innate and adaptive immune responses (FIG. 4) . Broadly speaking, these mechanisms can be grouped into four classes. The first type of mechanism is the depletion of nutrients required by lymphocytes -specifically, l-arginine depletion through ARG1-dependent consumption 49 and l-cysteine deprivation via its consumption and sequestration 111 . The depletion of these amino acids causes downregulation of the ζ-chain in the T cell receptor (TCR) complex and proliferative arrest of antigen-activated T cells.
The second type of mechanism is the generation of oxidative stress, which is caused by the production of ROS and reactive nitrogen species by MDSCs. Peroxynitrite and hydrogen peroxide are produced by the combined and cooperative activities of NADPH oxidase, ARG1 and iNOS in different MDSC subsets, and these reactive species drive several molecular blocks in T cells, ranging from the loss of TCR ζ-chain expression 112 The third type of mechanism interferes with lymphocyte trafficking and viability. Expression of ADAM17 (disintegrin and metalloproteinase domaincontaining protein 17) at the plasma membrane of MDSCs decreases CD62L expression on the surface of naive CD4 + and CD8 + T cells, thereby limiting T cell recirculation to lymph nodes 114 . Another example is the modification of CCL2 by MDSC-derived peroxynitrite, a process that impairs the migration of effector CD8 + T cells to the tumour core 102 . Furthermore, MDSCs express galectin 9, which binds to T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) on lymphocytes and induces T cell apoptosis 115 . MDSCs also decrease the number and inhibit the function of mouse and human NK cells, mostly through membrane contact-dependent mechanisms (that is, through membrane-bound TGFβ (in the case of mouse MDSCs) and through interaction with the NK cell receptor NKp30 (also known as NCR3)) [116] [117] [118] . The fourth type of mechanism is the activation and expansion of T Reg cell populations. MDSCs promote the clonal expansion of antigen-specific natural T Reg cells and also induce the conversion of naive CD4 + T cells into induced T Reg cells. The mechanisms are not completely understood, but may involve cell-to-cell contact (including CD40-CD40L interactions) 119 , the production of soluble factors (such as IFNγ, IL-10 and TGFβ) by MDSCs 120 and possibly also the expression of ARG1 by MDSCs 121 (FIG. 4) 122 . In peripheral lymphoid organs, MDSC-mediated suppression of CD8 + T cells is usually antigen specific and requires the presentation of antigens by MDSCs and direct MDSC-T cell contact 101, 123 . By contrast, in the periphery 124 and at the tumour site 109, 110, 125, 126 , the activity of MDSCs is enhanced by activated T cells, and as a result MDSCs are able to suppress nearby T cells in an antigen-nonspecific manner. However, if T cells are activated and begin to express FAS ligand (also known as CD95L), they may induce the apoptosis of FAS The downregulation of IL-12 is exacerbated by the macrophages themselves, as macrophages promote the production of IL-10 by MDSCs (FIG. 4) . As MDSC potency is increased by inflammation 128 , it is not unexpected that inflammation enhances the crosstalk between MDSCs and macrophages. Inflammation mediates these effects by upregulating the expression of CD14 and increasing signalling through the TLR4 pathway in MDSCs 129 . MDSCs similarly impair DC function by producing IL-10, which inhibits TLR-induced IL-12 production by DCs and reduces DC-mediated activation of T cells 130 .
Mechanisms of tumour impact on myeloid cells
Neoplastic cells and tumour-associated stromal cells release multiple tumour-derived soluble factors that perturb the myeloid compartment. Cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, M-CSF, stem cell factor (SCF; also known as KIT ligand), VEGF and IL-3 promote myelopoiesis and contribute, in part, to a blockade of myeloid cell maturation 86, 105 (FIG. 5) . Tumour-derived soluble factors that are pro-inflammatory (such as IL-1β, IL-6, S100A8 and S100A9) [131] [132] [133] , as well as cytokines released by activated T cells (such as IFNγ, IL-4, IL-10 and IL-13) 125 , initiate the immunosuppressive pathways that commit immature myeloid cells to become MDSCs and then further promote the differentiation of MDSCs towards immunosuppressive macrophages and DCs (FIG. 5) . The tumour-derived factors CCL2, CCL12, CXC-chemokine ligand 5 (CXCL5), pro kineticin 2, S100A8 and S100A9 recruit immature myeloid cells to the tumour stroma 68, 134, 135 (FIG. 5) , with signal transducer and activator of transcription 3 (STAT3) playing a major role. Early studies identified STAT3 as a crucial regulator of DC and macrophage defects 139, 140 and MDSC population expansion [141] [142] [143] . STAT3 not only prevents apoptosis and promotes cell proliferation by upregulating the antiapoptotic or pro-proliferative factors B cell lymphoma XL (BCL-XL), MYC, cyclin D1 and survivin 105, 144 , but also regulates the expression of multiple proteins that are crucial for the differentiation of myeloid cells. One such pathway involves the calcium-binding pro-inflammatory proteins S100A8 and S100A9 (REF. 145 ). STAT3-mediated upregulation of these proteins in myeloid progenitors inhibits DC differentiation and promotes MDSC accumulation 146 . S100A8 and S100A9 also enhance the suppressive activity of MDSCs and recruit MDSCs to the tumour site 132 . Myeloid cell NADPH oxidase is another important target of STAT3. STAT3-mediated upregulation of the NADPH oxidase components p47phox (also known as NCF1) and gp91phox (also known as CYBB) increases ROS levels, thereby making MDSCs more suppressive 90 . STAT3 also downregulates protein kinase Cβ isoform II (PKCβII), which is required for DC differentiation, and thus prevents the development of DCs into mature cells 147 . In addition, STAT3 regulates the transcription factor Nature Reviews | Immunology The calcium-binding proteins S100A8 and S100A9 are involved in the chemotaxis of MDSCs and other myeloid cells; these effects are mediated in part through the activation of receptor for advanced glycation end-products (RAGE). At the same time, S100A8 and S100A9 along with gp91phox are part of the NADPH oxidase (NOX) complex that is responsible for the increased production of reactive oxygen species (ROS) by MDSCs. b | Tumour-associated myeloid cells deprive T cells of amino acids that are essential for their growth and differentiation. c | Tumour-associated myeloid cells release oxidizing molecules, such as hydrogen peroxide (H 2 O 2 ) and peroxynitrite (ONOO -). Peroxynitrite causes nitration and nitrosylation of components of the T cell receptor (TCR) signalling complex, and H 2 O 2 causes the loss of the TCR ζ-chain, thereby inhibiting T cell activation through the TCR. d | Tumour-associated myeloid cells can also interfere with T cell migration and viability. The metalloproteinase ADAM17 (disintegrin and metalloproteinase domain-containing protein 17) cleaves CD62L, which is necessary for T cell migration to draining lymph nodes, and galectin 9 (GAL9) can engage T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) on T cells to induce apoptosis. As the induction of the immunosuppressive pathways that are depicted in the figure is regulated by common transcription factors, these pathways can operate in more than one myeloid cell type ( see FIG. 5 ). ARG1, arginase 1; ASC, asc-type amino acid transporter; CAT2B, cationic amino acid transporter 2 isoform 1 (l-arginine transporter); CCL2, CC-chemokine ligand 2; CCR2, CC-chemokine receptor 2; C/EBPβ, CCAAT/enhancer-binding protein-β; EIF2A, eukaryotic translation initiation factor 2A; ERK2, extracellular signal-regulated kinase 2; FOXP3, forkhead box P3; HIF1α, hypoxia-inducible factor 1α; HuR, Hu-antigen R (also known as ELAVL1); IL, interleukin; IL-2R, IL-2 receptor; iNOS, inducible nitric oxide synthase; mTOR, mammalian target of rapamycin; MYD88, myeloid differentiation primary-response protein 88; NK, natural killer; PI3K, phosphoinositide 3-kinase; STAT, signal transducer and activator of transcription; TGFβ, transforming growth factor-β; Xc -, cystine-glutamate transporter. These transcription factors, in turn, regulate the synthesis of their protein targets, thereby affecting myeloid cell functions. ARG1, arginase 1; BCL-XL, B cell lymphoma XL; C/EBPβ, CCAAT/enhancer-binding protein-β; DC, dendritic cell; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSP70, heat-shock protein 70; IFNγ, interferon-γ; IL, interleukin; iNOS, inducible nitric oxide synthase; MDSC, myeloid-derived suppressor cell; NF-κB, nuclear factor-κB; NO, nitric oxide; NOX2, NADPH oxidase 2; PGE2, prostaglandin E2; PKCβII, protein kinase Cβ isoform II; ROS, reactive oxygen species; STAT, signal transducer and activator of transcription; TAM, tumour-associated macrophage; TGFβ, transforming growth factor-β; TLR, Toll-like receptor; VEGF, vascular endothelial growth factor.
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CCAAT/enhancer-binding protein-β (C/EBPβ). C/EBPβ regulates myelopoiesis in healthy individuals 148 and has a crucial role in controlling the differentiation of myeloid progenitors to functional MDSCs 131 . STAT3 is responsible, at least in part, for inducing the expansion of MDSC populations via upregulation of C/EBPβ and also has an indirect role in myeloid cell mobilization, accumulation and survival 149 .
The transcription factor STAT1 regulates subsets of myeloid cells through its effects on iNOS expression and is crucial for immune suppression by macrophages and MDSCs 81, 108, 125 . Other characteristics of MDSCs and macrophages (including upregulated expression of ARG1 and increased TGFβ production 121, 153 ), and possibly the expansion of MDSC populations 154 , are controlled by STAT6. IL-4-induced polarization of TAMs activates STAT6, which binds to the promoter of the gene encoding the demethylase jumonji domain-containing protein 3 (JMJD3; also known as KDM6B). Activated JMJD3 demethylates histone H3 lysine 27 at specific genetic loci, and this increases the expression of ARG1, YM1 and FIZZ1, resulting in M2 polarization 155 . However, the genetic ablation of Jmjd3 in mice causes a defect in interferonregulatory factor 4 (IRF4)-dependent M2 polarization in response to M-CSF, helminth infection or chitin administration, but not following IL-4 stimulation, suggesting a more complex regulatory network 156 . The TLR family also has a prominent role in myeloid cell development, primarily via the activation of myeloid differentiation primary-response protein 88 (MYD88) and the downstream induction of nuclear factor-κB (NF-κB). NF-κB signalling is important for the mobilization of myeloid cells to sites of infection, injury or tumour growth 157, 158 . TLR4 regulates the inflammation-driven suppressive potency of MDSCs through an NF-κB-dependent mechanism 129 . The pro-inflammatory mediators COX2 and PGE2, which enhance MDSC accumulation and suppressive activity 137, [159] [160] [161] , are also potential targets for NF-κB 162 .
Autochthonous tumour
Differently from transplanted tumours, which arise from the experimental transfer of neoplastic cells or tissues, autochthonous tumours develop spontaneously in the host. Autochthonous tumours can be derived from either chemical carcinogenesis or targeted tissue expression of oncogenes by genetic manipulation of mice.
Model of MDSC involvement in tumour progression
Recent studies of autochthonous tumour formation in transgenic mice indicate that cells with an MDSC phenotype probably intervene in the very early stages of cancer progression. Mice with autochthonous pancreatic cancer undergo progressive waves of myeloid cell recruitment after the initiation of the transforming programme driven by the Kras oncogene 163 . Recruited myeloid cells contribute to the local production of IL-6 and IL-11, which activate STAT3. STAT3, in turn, induces antiapoptotic and pro-proliferative genes, fuelling tumour initiation, promotion and progression 164, 165 . During the early events of colitis-associated cancer, myeloid cells act as tumour promoters by enhancing the proliferation of tumour-initiating cells and by protecting premalignant intestinal epithelial cells from apoptosis 166 . In thyroid carcinomas, the oncogenic fusion protein RET/PTC3 directly induces the production of CCL2 and GM-CSF, which together promote the recruitment of CD11b
+ myeloid cells that can promote tumour progression 167, 168 . An important question is whether these early recruited cells are immunosuppressive MDSCs. Unfortunately, only a few studies in autochthonous tumour models have determined the immunosuppressive activity of the tumourassociated CD11b + GR1
+ cells. In models of spontaneous breast, pancreatic or lung cancer, accumulated myeloid cells had both the phenotype and immunosuppressive features of MDSCs 109, 163, 169 . Moreover, in a recent study, conditional deletion of the gene encoding p120 catenin (a protein involved in cell-cell adhesion and signal transduction) in mice caused the formation of invasive squamous cell cancer and desmoplasia and the associated production of CCL2, GM-CSF, M-CSF and TNF. These events resulted in the accumulation of immuno suppressive CD11b + GR1 + CD124 + MDSCs that promoted tumour progression by activating stromal fibroblasts 
CD11c
-MDSCs were the most abundant leukocyte subtype in premalignant skin, and they also accumulated progressively in the spleen. However, these cells failed to inhibit the polyclonal activation of either CD4 + or CD8 + T cells and did not produce ROS 60 . These results, together with the data discussed above from transplantable tumour models, support a two-stage model of MDSC involvement in cancer. An almost universal feature of tumour progression is the activation of abnormal myelopoiesis and the recruitment of immature myeloid cells into tissues. This process is governed by diverse soluble factors and is dependent on the upregulation of STAT3 and other key transcription factors (FIG. 5) .
Myelopoiesis during acute infection, stress or trauma results in rapid terminal differentiation of myeloid cells. By contrast, cancer myelopoiesis is associated with defective myeloid cell differentiation, which results in the accumulation and persistence of immature myeloid cells. Although necessary, these events are not sufficient to generate immunosuppressive MDSCs: activation of the immature myeloid cells via a network of regulatory mechanisms is also required (FIG. 5) . The activation of these mechanisms in mice with most transplantable tumours and many, but not all, spontaneous tumours results in the accumulation of immunosuppressive MDSCs. In tumour sites, these cells further differentiate into TAMs and possibly into suppressive DCs. In patients with cancer, cells with an MDSC phenotype are almost universally immunosuppressive, which may reflect their isolation from patients with advanced disease. If immuno suppressive activity is not a property of the first wave of immature myeloid cells recruited to tumours, continuous stimulation of myelopoiesis and activation of immature myeloid cells by tumour-derived soluble factors may drive the subsequent accumulation of immunosuppressive MDSCs that support tumour promotion and form the metastatic niche. Accordingly, the oncogenic programme may have a greater influence on the functional immunosuppressive activities of MDSCs than on their accumulation.
The transition from immature myeloid cell to MDSC might be defective in some experimental tumour models, and different oncogenic programmes may differentially affect the kinetics of immature myeloid cell to MDSC conversion. Treatment in vitro with combinations of GM-CSF, G-CSF, IL-6 and IL-13 induces the rapid differentiation of human and mouse bone marrow precursor cells into cells that resemble MDSCs 89, 131, 137, 171 . These studies may provide the framework for identifying the key molecules that govern MDSC maturation.
Therapeutic targeting of myeloid cells
It is increasingly clear that successful cancer immunotherapy will require limiting the immunosuppressive effects of populations of myeloid cells. Knowledge of the molecular mechanisms responsible for the accumulation of MDSCs and immunosuppressive macrophages and DCs in cancer has allowed for therapeutic targeting of these cells. This targeting is focused on six main goals. The first goal is to inhibit the molecular mechanisms used by myeloid cells to block lymphocyte reactivity and proliferation. Second, targeting should inhibit the generation of MDSCs from bone marrow progenitors or induce the apoptosis of circulating MDSCs. Third, it should force MDSCs to mature into proficient APCs that can stimulate tumour-specific T cells. Fourth, it should prevent the trafficking of myeloid cells from the bone marrow to peripheral lymphoid organs and to tumours. The fifth goal is to repolarize or eliminate TAMs and replace them with pro-inflammatory M1 macrophages that enhance antitumour immune responses. Finally, the sixth goal is to restore the antigen-presenting capabilities of DCs and macrophages, allowing these populations to activate effector T cell responses (TABLE 2) .
The proposed two-stage model for MDSC involvement might have implications for the further development of therapies. Some immunosuppressive mechanisms are common to all myeloid cells, but others are unique to individual populations. Therefore, targeting common effector molecules is likely to be more effective than targeting individual suppressive pathways. TAM reprogramming 194, 195 Conclusions and perspective It is not clear whether abnormal myelopoiesis and the pathological activation of myeloid cells are temporally regulated. Do cancer cells first condition mature leukocytes, MDSCs, DCs and macrophages that are then recruited in response to suppressive factors produced by the progressing tumour? Or, do the two processes occur concurrently and are MDSCs recruited as a pre requisite to tumour progression? More sophisticated tumour models and techniques will be required to address this key question.
It is clear that the myeloid lineage is globally altered in cancer as a single, closely integrated system involving all terminally differentiated myeloid cells and their pathologically activated immature progenitors. Although there are a multitude of phenotypical and functional changes in different myeloid cell subpopulations, these changes are governed by common tumour-derived suppressive factors and transcriptional programmes. These commonalities provide an opportunity for therapeutic interventions that may concomitantly normalize multiple myeloid cell abnormalities. ARG1, arginase 1; CCL, CC-chemokine ligand; CCR2, CC-chemokine receptor 2; CSF1R, macrophage colony-stimulating factor receptor; CTL, cytotoxic T lymphocyte; CXCL, CXC-chemokine ligand; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon-γ; IκB, NF-κB inhibitor; IL, interleukin; iNOS, inducible nitric oxide synthase; MDSC, myeloid-derived suppressor cell; MMP, matrix metalloproteinase; NF-κB, nuclear factor-κB; NK, natural killer; NO, nitric oxide; PGE2, prostaglandin E2; ROS, reactive oxygen species; SCF, stem cell factor; STAT, signal transducer and activator of transcription; TAM, tumour-associated macrophage; TGFβ, transforming growth factor-β; TIMP1, tissue inhibitor of metalloproteinases 1; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor. *Human cancers are indicated; other studies were conducted in mouse models. 
